How Many People Experience Side Effects from Wegovy

Step 1: understanding what the STEP 1 trial actually measured

The clearest population-level data comes from the STEP 1 trial, a 68-week study of 1,961 adults with obesity who received either semaglutide 2.4 mg or placebo, both alongside lifestyle changes. The trial, published in the New England Journal of Medicine, found that gastrointestinal events affected roughly 74% of the semaglutide group against around 48% on placebo. That gap is real, but context matters.

A few things are worth pulling out of that headline. First, the 74% figure counts anyone who reported a GI event at any point during the entire 68 weeks, not people who were constantly unwell. Second, the most common individual events were nausea (reported by about 44%), diarrhoea (about 30%), vomiting (about 24%) and constipation (about 24%). Third, discontinuation due to GI side effects happened in roughly 4.5% of participants, so the overwhelming majority stayed on treatment despite the discomfort. That's a notably different picture from "most people feel terrible and stop".

Nausea tends to be front-loaded: it's most noticeable in the first few weeks of a new or increased dose, then settles as the body adjusts. The slow titration schedule (doses stepping up roughly every four weeks) exists precisely because managing Wegovy side effects is much easier when the increase is gradual.

Step 2: moving beyond the gut, the full side-effect picture

Gastrointestinal events dominate the reporting, but Wegovy's side-effect profile includes other areas too. Headache and fatigue are fairly common early on, often tied to reduced calorie intake rather than the medicine itself. Injection-site reactions (redness, itching, bruising) affect a minority of people and rarely cause lasting trouble. The full list of reported effects also includes dizziness and burping, both of which most people find manageable.

Less common but more serious: gallbladder problems (gallstones and cholecystitis) occur at higher rates in people losing weight rapidly, regardless of method, but the STEP programme recorded higher rates in the semaglutide groups than placebo. Heart rate can increase modestly at higher doses, something a prescriber factors in during assessment. Pancreatitis is rare but serious; the MHRA's January 2026 Drug Safety Update on GLP-1 medicines specifically highlighted this risk, advising patients and clinicians to be alert to severe, persistent stomach pain that spreads to the back.

Psychological side effects (low mood, changes in eating relationship) are reported by some people, and Wegovy is not recommended for anyone with a history of certain mental health conditions without careful clinical discussion. This is exactly the sort of thing a prescriber weighs up before approving treatment, not afterwards.

Step 3: what a 'when to get medical help' list actually looks like in practice

Mild nausea and loose stools in week one do not need a GP call. A lot of people quietly manage those, drink more water, eat smaller meals, and feel considerably better by week three. What does need prompt attention is a different category entirely.

Get medical help the same day if you develop severe abdominal pain, especially pain that radiates through to your back, with or without vomiting, this can signal pancreatitis. Seek urgent care for signs of an allergic reaction: swelling of the face, lips or throat, difficulty breathing, or a rapidly spreading rash. Some people also notice cold-like symptoms alongside other early side effects, which can feel alarming but are worth discussing with a clinician to rule out anything more serious. Symptoms of dehydration from persistent vomiting or diarrhoea (dizziness when standing, very dark urine, confusion) also warrant medical contact rather than waiting it out. Jaundice or severe upper-right abdominal pain may indicate a gallbladder problem.

For anything less acute, the aftercare team at our pharmacy is available seven days a week to answer questions between doses. And if a side effect surprises you or seems unusual, reporting it via the MHRA's Yellow Card scheme takes only a few minutes and contributes to national safety monitoring, something that matters for a medicine that's still relatively new in wide use. You can also use Yellow Card to flag any suspected counterfeit or suspect product.

Step 4: putting the numbers in proportion before you decide

If you've reached this page feeling slightly daunted by the statistics, that's a reasonable place to be. The data does show a clear signal, semaglutide causes more GI upset than placebo, and that's not a small effect. What the data also shows is that the vast majority of people tolerate it well enough to stay on treatment and reach a maintenance dose, and that serious events are genuinely uncommon rather than a theoretical footnote.

The NHS's patient-level information on semaglutide sets out the side-effect list in plain language and is a solid starting point. For people who'd like to understand the percentage breakdown in more detail, or who want to know whether some people have no side effects at all, we've covered both questions properly in their own pages.

Our prescribers go through your medical history, current medicines and any relevant conditions before any prescription is issued, side-effect risk is part of that conversation, not a follow-up thought. If you'd like to explore whether Wegovy is clinically appropriate for you, start a free consultation and a GPhC-registered prescriber will review your answers the same day.